Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial | AVESİS

Dokuz Eylül University Research Information System

Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

Copy For Citation

Vico M. R., Wetterskog D., Thakali S., Orlando F., Jayaram A. K., Vainauskas O., ...More

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023

Publication Type: Conference Paper / Summary Text
Doi Number: 10.1016/j.annonc.2023.09.2784
City: Barcelona
Country: Spain
Dokuz Eylül University Affiliated: Yes